QQQ   414.08 (-2.20%)
AAPL   165.02 (-1.21%)
MSFT   399.11 (-1.28%)
META   481.95 (-3.96%)
GOOGL   154.23 (-1.14%)
AMZN   174.65 (-2.55%)
TSLA   147.13 (-1.87%)
NVDA   763.66 (-9.81%)
AMD   146.71 (-5.40%)
NIO   3.80 (-5.00%)
BABA   69.06 (+0.26%)
T   16.50 (+1.04%)
F   12.14 (+0.66%)
MU   106.90 (-4.49%)
GE   148.08 (-3.18%)
CGC   7.97 (+1.79%)
DIS   112.58 (+0.13%)
AMC   3.18 (+8.90%)
PFE   25.97 (+2.28%)
PYPL   62.26 (+0.26%)
XOM   119.97 (+1.22%)
QQQ   414.08 (-2.20%)
AAPL   165.02 (-1.21%)
MSFT   399.11 (-1.28%)
META   481.95 (-3.96%)
GOOGL   154.23 (-1.14%)
AMZN   174.65 (-2.55%)
TSLA   147.13 (-1.87%)
NVDA   763.66 (-9.81%)
AMD   146.71 (-5.40%)
NIO   3.80 (-5.00%)
BABA   69.06 (+0.26%)
T   16.50 (+1.04%)
F   12.14 (+0.66%)
MU   106.90 (-4.49%)
GE   148.08 (-3.18%)
CGC   7.97 (+1.79%)
DIS   112.58 (+0.13%)
AMC   3.18 (+8.90%)
PFE   25.97 (+2.28%)
PYPL   62.26 (+0.26%)
XOM   119.97 (+1.22%)
QQQ   414.08 (-2.20%)
AAPL   165.02 (-1.21%)
MSFT   399.11 (-1.28%)
META   481.95 (-3.96%)
GOOGL   154.23 (-1.14%)
AMZN   174.65 (-2.55%)
TSLA   147.13 (-1.87%)
NVDA   763.66 (-9.81%)
AMD   146.71 (-5.40%)
NIO   3.80 (-5.00%)
BABA   69.06 (+0.26%)
T   16.50 (+1.04%)
F   12.14 (+0.66%)
MU   106.90 (-4.49%)
GE   148.08 (-3.18%)
CGC   7.97 (+1.79%)
DIS   112.58 (+0.13%)
AMC   3.18 (+8.90%)
PFE   25.97 (+2.28%)
PYPL   62.26 (+0.26%)
XOM   119.97 (+1.22%)
QQQ   414.08 (-2.20%)
AAPL   165.02 (-1.21%)
MSFT   399.11 (-1.28%)
META   481.95 (-3.96%)
GOOGL   154.23 (-1.14%)
AMZN   174.65 (-2.55%)
TSLA   147.13 (-1.87%)
NVDA   763.66 (-9.81%)
AMD   146.71 (-5.40%)
NIO   3.80 (-5.00%)
BABA   69.06 (+0.26%)
T   16.50 (+1.04%)
F   12.14 (+0.66%)
MU   106.90 (-4.49%)
GE   148.08 (-3.18%)
CGC   7.97 (+1.79%)
DIS   112.58 (+0.13%)
AMC   3.18 (+8.90%)
PFE   25.97 (+2.28%)
PYPL   62.26 (+0.26%)
XOM   119.97 (+1.22%)
ASX:PNV

PolyNovo (PNV) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
3.38 million shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
6.86%
Price Target
N/A
PNV stock logo

About PolyNovo Stock (ASX:PNV)

PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell Implant to host pancreatic islet cells in the skin; NovoSorb MTX for the treatment of varying complex wounds; and plastics and reconstructive device product. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.

PNV Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
PolyNovo Limited (PNV.AX)
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Is PolyNovo Limited (ASX:PNV) Potentially Undervalued?
Polynovo Ltd (MFJ.SG)
PNV.AX - PolyNovo Limited
See More Headlines
Receive PNV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PolyNovo and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Devices
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
237
Year Founded
N/A

Profitability

Net Income
$1.59 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$83.47 million
Book Value
A$0.10 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
1.65
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Swami Raote BPHARM
    M.B.A., CEO & Director
  • Mr. Jan-Marcel Gielen C.A.
    CFO & Company Secretary
  • Dr. David McQuillan Ph.D.
    Chief Technical & Scientific Officer
  • Mr. Philip Scorgie
    Chief Information Officer
  • Mr. Ahmed Hassan
    Director of Operations
  • Ms. Teena Chadha
    APAC Marketing & Distributor Manager
  • Ms. Monica Benyk
    HR Manager
  • Dr. Tim Moore
    Principal Scientist
  • Mr. Edward Graubart
    Senior Vice President of Sales & Marketing (Americas)

PNV Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of PolyNovo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PolyNovo investors own include Immutep (IMMP), Rural Funds Group (RFF), Vanguard FTSE Pacific ETF (VPL), UQM Technologies (UQM), Tesla (TSLA), Starpharma (SPL), Moelis Australia (MOE), iSignthis (ISX), Align Technology (ALGN) and Acasti Pharma (ACST).

This page (ASX:PNV) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners